Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 219 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Cancer Surgery Unexpectedly Canceled for Mother of Two, Who Says It’s... March 31, 2020 How I Learned to Cope With Survivor’s Guilt After Cancer January 27, 2021 Evaluating Targeted Therapy for People With Advanced Gastric or Gastroesophageal Junction... March 21, 2023 Mesothelioma Awareness Day: Spotlight on the PrE0506/DREAM3R Clinical Trial September 23, 2021 Load more HOT NEWS Διαφημιστείτε Facing the future: “How can a 3-year old understand that her... PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable... Coping With the Holidays During COVID-19 and Cancer
